Chronic Hepatitis C
There are approximately 170 million people or 3% of the world’s population infected with hepatitis C virus (HCV) (World Health Organization, WHO) with more than 365,000 deaths per year resulting from long-term complications such as cirrhosis and hepatocellular carcinoma
The investigational drug being developed is an orally administered anti-HCV therapeutic which retains potent antiviral activity against most HCV replicons that show resistance to other direct-acting antiviral agents.
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of the investigational product.
This is a phase 2a, randomized, open-label clinical study.
Duration : 48 weeks
Men and women between 18 and 65 years of age
Chronic Hepatitis C with genotype 1 or 3 with or without compensated liver cirrhosis
Untreated or treatment experienced for Hepatitis C